Knowhow offering
|
| Title | New drug target & promising chemical starting point for treating cancer - PIP3 Antagonists |
| Knowhow is available for | A new therapeutic strategy that identifies a new drug target and development of various promising small molecules that show promising results in animal testing to be further developed into drugs for treatment of cancer. |
| Summary | Our technology looks at identifying a new strategy and potential drug molecules that target lipid-protein interactions (PIP3/protein binding) as a therapeutic tactic. We have also developed promising chemical leads (small molecule antagonists for PIP3/protein binding) – which inhibit cancer cell survival, resulting in significant antitumor activity in vivo as well as a set of small molecule non-lipid antagonists of lipid-protein interactions, which can be used to design specific drugs |
| Advantages | • Can selectively inhibit PIP3-mediated signaling
• Found to be able to target a wide range of PIP3-dependent signaling events in vitro
• Significant anti-tumour activity in vivo
• Exhibit improved activity /PH domain selectivity compared to previously identified antagonists
• Promising chemical starting points that have been optimized, that have undergone successful animal trials
|
|
Knowhow is listed under following categories
|
Knowhow from
| CSIR-NCL, Pune |
| Scientific/ engineering subject areas |
Life sciences/ biosciences & engineering ; Chemical sciences & engineering |
| Investor interest categories |
Materials Technology including Nanotechnology ; Biotechnology/ Biomedical/ Health Technologies |
| Industries |
Pharmaceuticals, Bulk Drugs, Formulations ; |